Pharmacological intervention of the HMGB1-pCTS-L axis to ameliorate inflammatory diseases - Takeaways - MDSpire

Pharmacological intervention of the HMGB1-pCTS-L axis to ameliorate inflammatory diseases

  • By

  • Weiqiang Chen

  • Jianhua Li

  • Xiaoling Qiang

  • Li Lou

  • Cassie Shu Zhu

  • Meihong Deng

  • Haichao Wang

  • May 8, 2026

  • 0 min

Share

  • 1

    Dysregulated inflammation is central to diseases like sepsis and rheumatoid arthritis, necessitating novel therapeutic approaches.

  • 2

    The HMGB1-pCTS-L axis is crucial in mediating dysregulated inflammation, activating the non-canonical NF-κB pathway.

  • 3

    Tetranectin inhibits HMGB1 release but promotes pyroptosis, highlighting the complexity of targeting inflammatory pathways.

  • 4

    The TN-derived P2–1 peptide selectively inhibits the HMGB1-pCTS-L axis, offering a targeted approach to treat sepsis and RA.

  • 5

    Next-generation therapies targeting HMGB1 and pCTS-L represent promising interventions for a range of inflammatory diseases.

Original Source(s)

Pharmacological intervention of the HMGB1-pCTS-L axis to ameliorate inflammatory diseases

  • by Weiqiang Chen, Jianhua Li, Xiaoling Qiang, Li Lou, Cassie Shu Zhu, Meihong Deng, Haichao Wang

  • May 8, 2026

Related Content

NPs Top US Jobs List Again

The nurse practitioner profession claims the No. 1 spot across three categories in the U.S. News & World Report 2026 Best Jobs rankings for the third consecutive year.

AI Scribes: Efficiency for Whom?

Unresolved safety, privacy, and regulatory concerns may limit benefits of AI scribes for physicians and patients.

AI Scribes Lag Clinicians on Note Quality

A VHA study across 11 vendors finds AI-generated primary care notes score lower than clinician-written notes, with the largest deficits in thoroughness, organization, and usefulness